secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-020841
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics reports Q1 net loss of $30.1M; atacicept Phase 3 to start Q2 2023
--------------------------------------------------------------------------------

- Net loss of $30.1M ($0.80 per diluted share) vs $17.1M ($0.71) in Q1 2022.
- Cash, cash equivalents, and marketable securities of $197.2M as of March 31, 2023; expected to fund operations to early 2026.
- 36-week data from Phase 2b ORIGIN trial of atacicept in IgAN selected as late-breaking presentation at ERA Congress 2023.
- Plan to initiate pivotal Phase 3 trial of atacicept in IgAN in Q2 2023.
- Appointed Kerry Cooper, M.D., as Senior Vice President of Medical Affairs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017023020841/0000950170-23-020841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017023020841/vera-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer